FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3197266306> ?p ?o ?g. }

• W3197266306 endingPage "S364" @default.
• W3197266306 startingPage "S363" @default.
• W3197266306 abstract "Context: Pelabresib (CPI-0610) is a potent, selective BET bromodomain inhibitor under investigation in the ongoing Phase 2 MANIFEST trial, given as monotherapy to ruxolitinib (rux)-intolerant/refractory myelofibrosis (MF) pts in arm 1, as an “add-on” to rux in MF pts who have suboptimal/lost response to rux in arm 2, and as combination therapy with rux in JAKi-naïve MF pts in arm 3. Objective: We assessed activity of pelabresib, including changes in inflammatory cytokines (Ck) in blood, improvement of bone marrow (BM) biology, including fibrosis (BMF), erythroid (Ery) progenitor and megakaryocyte (MK) numbers and clustering, and impact of mutational status on clinical response. Results: Rapid PD response was demonstrated by median blood IL8 mRNA level reduced to 55% of baseline (BL) levels 4 hours post-1st dose of pelabresib in 102 pts, with similar reduction across arms. Elevated blood Ck levels were observed at BL across arms. Reduction of NF-κB and non-NF-κB regulated inflammatory Ck was observed on cycle 1 day 14 (C1D14) across arms and maintained through C9D1 (24 weeks). BMF grading was assessed by local pathologists for BL and post-treatment (most at 24 weeks) biopsies from 116 evaluable pts. Relative BMF improvement of ≥1 grade was observed in 33% (38/116) of all pts, with 21% (6/29) in arm 1, 41% (16/39) in arm 2, and 33% (16/48) in arm 3. BMF grade worsening was observed in only 6% (7/116) pts. Exploratory analyses of Ery and MK lineages by immunohistochemical staining for CD71 and CD61, respectively, on BM biopsy pairs (BL and week 24) revealed an increase in Ery progenitors in 59% (22/37) of pts. Tight clusters of MK, characteristic in MF BM, were observed at BL, and improvement in MK numbers and/or clustering was observed in 65% (24/37) pts. Mutation analysis revealed similar profiles at BL across arms. SVR35 at 24 weeks was similar, regardless of mutational status for each of the 14 genes analyzed. Conclusions: Our data demonstrate a robust PD effect of pelabresib in MF pts, indicate broad clinical responses irrespective of mutational status, and suggest the disease-modifying potential of pelabresib by improving BM fibrosis and function. Pelabresib (CPI-0610) is a potent, selective BET bromodomain inhibitor under investigation in the ongoing Phase 2 MANIFEST trial, given as monotherapy to ruxolitinib (rux)-intolerant/refractory myelofibrosis (MF) pts in arm 1, as an “add-on” to rux in MF pts who have suboptimal/lost response to rux in arm 2, and as combination therapy with rux in JAKi-naïve MF pts in arm 3. We assessed activity of pelabresib, including changes in inflammatory cytokines (Ck) in blood, improvement of bone marrow (BM) biology, including fibrosis (BMF), erythroid (Ery) progenitor and megakaryocyte (MK) numbers and clustering, and impact of mutational status on clinical response. Rapid PD response was demonstrated by median blood IL8 mRNA level reduced to 55% of baseline (BL) levels 4 hours post-1st dose of pelabresib in 102 pts, with similar reduction across arms. Elevated blood Ck levels were observed at BL across arms. Reduction of NF-κB and non-NF-κB regulated inflammatory Ck was observed on cycle 1 day 14 (C1D14) across arms and maintained through C9D1 (24 weeks). BMF grading was assessed by local pathologists for BL and post-treatment (most at 24 weeks) biopsies from 116 evaluable pts. Relative BMF improvement of ≥1 grade was observed in 33% (38/116) of all pts, with 21% (6/29) in arm 1, 41% (16/39) in arm 2, and 33% (16/48) in arm 3. BMF grade worsening was observed in only 6% (7/116) pts. Exploratory analyses of Ery and MK lineages by immunohistochemical staining for CD71 and CD61, respectively, on BM biopsy pairs (BL and week 24) revealed an increase in Ery progenitors in 59% (22/37) of pts. Tight clusters of MK, characteristic in MF BM, were observed at BL, and improvement in MK numbers and/or clustering was observed in 65% (24/37) pts. Mutation analysis revealed similar profiles at BL across arms. SVR35 at 24 weeks was similar, regardless of mutational status for each of the 14 genes analyzed. Our data demonstrate a robust PD effect of pelabresib in MF pts, indicate broad clinical responses irrespective of mutational status, and suggest the disease-modifying potential of pelabresib by improving BM fibrosis and function." @default.
• W3197266306 created "2021-09-13" @default.
• W3197266306 creator A5001330715 @default.
• W3197266306 creator A5002632381 @default.
• W3197266306 creator A5008437556 @default.
• W3197266306 creator A5011529063 @default.
• W3197266306 creator A5013707401 @default.
• W3197266306 creator A5016229715 @default.
• W3197266306 creator A5023605713 @default.
• W3197266306 creator A5027545918 @default.
• W3197266306 creator A5034181399 @default.
• W3197266306 creator A5039057642 @default.
• W3197266306 creator A5040647870 @default.
• W3197266306 creator A5046772202 @default.
• W3197266306 creator A5046827092 @default.
• W3197266306 creator A5050259782 @default.
• W3197266306 creator A5057884333 @default.
• W3197266306 creator A5058388163 @default.
• W3197266306 creator A5061606864 @default.
• W3197266306 creator A5063723398 @default.
• W3197266306 creator A5072336042 @default.
• W3197266306 creator A5078816311 @default.
• W3197266306 creator A5084597185 @default.
• W3197266306 creator A5085521139 @default.
• W3197266306 creator A5087492053 @default.
• W3197266306 date "2021-09-01" @default.
• W3197266306 modified "2023-10-01" @default.
• W3197266306 title "MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial" @default.
• W3197266306 doi "https://doi.org/10.1016/s2152-2650(21)01835-8" @default.
• W3197266306 hasPublicationYear "2021" @default.
• W3197266306 type Work @default.
• W3197266306 sameAs 3197266306 @default.
• W3197266306 citedByCount "3" @default.
• W3197266306 countsByYear W31972663062022 @default.
• W3197266306 countsByYear W31972663062023 @default.
• W3197266306 crossrefType "journal-article" @default.
• W3197266306 hasAuthorship W3197266306A5001330715 @default.
• W3197266306 hasAuthorship W3197266306A5002632381 @default.
• W3197266306 hasAuthorship W3197266306A5008437556 @default.
• W3197266306 hasAuthorship W3197266306A5011529063 @default.
• W3197266306 hasAuthorship W3197266306A5013707401 @default.
• W3197266306 hasAuthorship W3197266306A5016229715 @default.
• W3197266306 hasAuthorship W3197266306A5023605713 @default.
• W3197266306 hasAuthorship W3197266306A5027545918 @default.
• W3197266306 hasAuthorship W3197266306A5034181399 @default.
• W3197266306 hasAuthorship W3197266306A5039057642 @default.
• W3197266306 hasAuthorship W3197266306A5040647870 @default.
• W3197266306 hasAuthorship W3197266306A5046772202 @default.
• W3197266306 hasAuthorship W3197266306A5046827092 @default.
• W3197266306 hasAuthorship W3197266306A5050259782 @default.
• W3197266306 hasAuthorship W3197266306A5057884333 @default.
• W3197266306 hasAuthorship W3197266306A5058388163 @default.
• W3197266306 hasAuthorship W3197266306A5061606864 @default.
• W3197266306 hasAuthorship W3197266306A5063723398 @default.
• W3197266306 hasAuthorship W3197266306A5072336042 @default.
• W3197266306 hasAuthorship W3197266306A5078816311 @default.
• W3197266306 hasAuthorship W3197266306A5084597185 @default.
• W3197266306 hasAuthorship W3197266306A5085521139 @default.
• W3197266306 hasAuthorship W3197266306A5087492053 @default.
• W3197266306 hasConcept C126322002 @default.
• W3197266306 hasConcept C143998085 @default.
• W3197266306 hasConcept C151730666 @default.
• W3197266306 hasConcept C2776112149 @default.
• W3197266306 hasConcept C2779343474 @default.
• W3197266306 hasConcept C2780007613 @default.
• W3197266306 hasConcept C2780076729 @default.
• W3197266306 hasConcept C71924100 @default.
• W3197266306 hasConcept C86803240 @default.
• W3197266306 hasConcept C90924648 @default.
• W3197266306 hasConceptScore W3197266306C126322002 @default.
• W3197266306 hasConceptScore W3197266306C143998085 @default.
• W3197266306 hasConceptScore W3197266306C151730666 @default.
• W3197266306 hasConceptScore W3197266306C2776112149 @default.
• W3197266306 hasConceptScore W3197266306C2779343474 @default.
• W3197266306 hasConceptScore W3197266306C2780007613 @default.
• W3197266306 hasConceptScore W3197266306C2780076729 @default.
• W3197266306 hasConceptScore W3197266306C71924100 @default.
• W3197266306 hasConceptScore W3197266306C86803240 @default.
• W3197266306 hasConceptScore W3197266306C90924648 @default.
• W3197266306 hasLocation W31972663061 @default.
• W3197266306 hasOpenAccess W3197266306 @default.
• W3197266306 hasPrimaryLocation W31972663061 @default.
• W3197266306 hasRelatedWork W1880500951 @default.
• W3197266306 hasRelatedWork W1883475886 @default.
• W3197266306 hasRelatedWork W2012828222 @default.
• W3197266306 hasRelatedWork W2115351357 @default.
• W3197266306 hasRelatedWork W2466699365 @default.
• W3197266306 hasRelatedWork W2557068058 @default.
• W3197266306 hasRelatedWork W2797422510 @default.
• W3197266306 hasRelatedWork W2939368495 @default.
• W3197266306 hasRelatedWork W3194195834 @default.
• W3197266306 hasRelatedWork W4296533651 @default.
• W3197266306 hasVolume "21" @default.
• W3197266306 isParatext "false" @default.
• W3197266306 isRetracted "false" @default.
• W3197266306 magId "3197266306" @default.
• W3197266306 workType "article" @default.